Modulatory effects of Pycnogenol® in a rat model of insulin-dependent diabetes mellitus: Biochemical, histological, and immunohistochemical evidences

Kehkashan Parveen, Tauheed Ishrat, Shabnam Malik, Mohd Adnan Kausar, Waseem A. Siddiqui

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A number of experimental and clinical findings have consistently demonstrated the protective effects of Pycnogenol® (PYC) in the management of diabetes. However, the protective mechanism by which PYC provides protection in a model type I diabetes has not been studied. This study examines the beneficial effect of PYC on hyperglycemia, inflammatory markers, and oxidative damage in diabetic rats. We also evaluated the possible mechanism of action of PYC which might be that it stimulates beta islet expression, which has been implicated in the process of insulin secretion and diabetes management. Diabetes was induced in rats by an intraperitoneal injection of streptozotocin (STZ; 60 mg/kg body weight) followed by free access to 5 % glucose for the next 24 h. Four days after STZ injection, rats were supplemented with PYC (10 mg/kg body weight) for 4 weeks. At the end of the experiment, blood was drawn, and rats were then sacrificed, and their livers and pancreases were dissected for biochemical and histological assays. The level of fasting blood glucose and glycosylated hemoglobin significantly increased but amylase, insulin, and hepatic glycogen level decreased in the STZ group. PYC significantly augmented these effects in STZ + PYC group. The STZ group showed elevated level of nitric oxide, tumor necrosis factor-α, and interleukin-1beta in serum which were decreased by PYC treatment. Moreover, PYC significantly ameliorated increased thiobarbituric reactive substances, protein carbonyl, and decreased levels of glutathione, glutathione-s-transferase, and catalase activity in the liver and pancreas of the STZ rats. Histopathological and immunohistochemical examination also revealed a remarkable protective effect of PYC. The study suggests that PYC is effective in reducing diabetic-related complications in a type I model of diabetes and might be beneficial for the treatment of diabetic patients.

Original languageEnglish (US)
Pages (from-to)347-360
Number of pages14
JournalProtoplasma
Volume250
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

insulin-dependent diabetes mellitus
Type 1 Diabetes Mellitus
animal models
diabetes
rats
pancreas
liver
protective effect
glutathione
body weight
tumor necrosis factors
insulin secretion
streptozotocin
hyperglycemia
intraperitoneal injection
blood serum
transferases
amylases
blood glucose
glycogen

All Science Journal Classification (ASJC) codes

  • Plant Science
  • Cell Biology

Cite this

Modulatory effects of Pycnogenol® in a rat model of insulin-dependent diabetes mellitus : Biochemical, histological, and immunohistochemical evidences. / Parveen, Kehkashan; Ishrat, Tauheed; Malik, Shabnam; Kausar, Mohd Adnan; Siddiqui, Waseem A.

In: Protoplasma, Vol. 250, No. 1, 01.01.2013, p. 347-360.

Research output: Contribution to journalArticle

Parveen, Kehkashan ; Ishrat, Tauheed ; Malik, Shabnam ; Kausar, Mohd Adnan ; Siddiqui, Waseem A. / Modulatory effects of Pycnogenol® in a rat model of insulin-dependent diabetes mellitus : Biochemical, histological, and immunohistochemical evidences. In: Protoplasma. 2013 ; Vol. 250, No. 1. pp. 347-360.
@article{204c5ea987584a33b67ce2b6f346ad4a,
title = "Modulatory effects of Pycnogenol{\circledR} in a rat model of insulin-dependent diabetes mellitus: Biochemical, histological, and immunohistochemical evidences",
abstract = "A number of experimental and clinical findings have consistently demonstrated the protective effects of Pycnogenol{\circledR} (PYC) in the management of diabetes. However, the protective mechanism by which PYC provides protection in a model type I diabetes has not been studied. This study examines the beneficial effect of PYC on hyperglycemia, inflammatory markers, and oxidative damage in diabetic rats. We also evaluated the possible mechanism of action of PYC which might be that it stimulates beta islet expression, which has been implicated in the process of insulin secretion and diabetes management. Diabetes was induced in rats by an intraperitoneal injection of streptozotocin (STZ; 60 mg/kg body weight) followed by free access to 5 {\%} glucose for the next 24 h. Four days after STZ injection, rats were supplemented with PYC (10 mg/kg body weight) for 4 weeks. At the end of the experiment, blood was drawn, and rats were then sacrificed, and their livers and pancreases were dissected for biochemical and histological assays. The level of fasting blood glucose and glycosylated hemoglobin significantly increased but amylase, insulin, and hepatic glycogen level decreased in the STZ group. PYC significantly augmented these effects in STZ + PYC group. The STZ group showed elevated level of nitric oxide, tumor necrosis factor-α, and interleukin-1beta in serum which were decreased by PYC treatment. Moreover, PYC significantly ameliorated increased thiobarbituric reactive substances, protein carbonyl, and decreased levels of glutathione, glutathione-s-transferase, and catalase activity in the liver and pancreas of the STZ rats. Histopathological and immunohistochemical examination also revealed a remarkable protective effect of PYC. The study suggests that PYC is effective in reducing diabetic-related complications in a type I model of diabetes and might be beneficial for the treatment of diabetic patients.",
author = "Kehkashan Parveen and Tauheed Ishrat and Shabnam Malik and Kausar, {Mohd Adnan} and Siddiqui, {Waseem A.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/s00709-012-0418-2",
language = "English (US)",
volume = "250",
pages = "347--360",
journal = "Protoplasma",
issn = "0033-183X",
publisher = "Springer Wien",
number = "1",

}

TY - JOUR

T1 - Modulatory effects of Pycnogenol® in a rat model of insulin-dependent diabetes mellitus

T2 - Biochemical, histological, and immunohistochemical evidences

AU - Parveen, Kehkashan

AU - Ishrat, Tauheed

AU - Malik, Shabnam

AU - Kausar, Mohd Adnan

AU - Siddiqui, Waseem A.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - A number of experimental and clinical findings have consistently demonstrated the protective effects of Pycnogenol® (PYC) in the management of diabetes. However, the protective mechanism by which PYC provides protection in a model type I diabetes has not been studied. This study examines the beneficial effect of PYC on hyperglycemia, inflammatory markers, and oxidative damage in diabetic rats. We also evaluated the possible mechanism of action of PYC which might be that it stimulates beta islet expression, which has been implicated in the process of insulin secretion and diabetes management. Diabetes was induced in rats by an intraperitoneal injection of streptozotocin (STZ; 60 mg/kg body weight) followed by free access to 5 % glucose for the next 24 h. Four days after STZ injection, rats were supplemented with PYC (10 mg/kg body weight) for 4 weeks. At the end of the experiment, blood was drawn, and rats were then sacrificed, and their livers and pancreases were dissected for biochemical and histological assays. The level of fasting blood glucose and glycosylated hemoglobin significantly increased but amylase, insulin, and hepatic glycogen level decreased in the STZ group. PYC significantly augmented these effects in STZ + PYC group. The STZ group showed elevated level of nitric oxide, tumor necrosis factor-α, and interleukin-1beta in serum which were decreased by PYC treatment. Moreover, PYC significantly ameliorated increased thiobarbituric reactive substances, protein carbonyl, and decreased levels of glutathione, glutathione-s-transferase, and catalase activity in the liver and pancreas of the STZ rats. Histopathological and immunohistochemical examination also revealed a remarkable protective effect of PYC. The study suggests that PYC is effective in reducing diabetic-related complications in a type I model of diabetes and might be beneficial for the treatment of diabetic patients.

AB - A number of experimental and clinical findings have consistently demonstrated the protective effects of Pycnogenol® (PYC) in the management of diabetes. However, the protective mechanism by which PYC provides protection in a model type I diabetes has not been studied. This study examines the beneficial effect of PYC on hyperglycemia, inflammatory markers, and oxidative damage in diabetic rats. We also evaluated the possible mechanism of action of PYC which might be that it stimulates beta islet expression, which has been implicated in the process of insulin secretion and diabetes management. Diabetes was induced in rats by an intraperitoneal injection of streptozotocin (STZ; 60 mg/kg body weight) followed by free access to 5 % glucose for the next 24 h. Four days after STZ injection, rats were supplemented with PYC (10 mg/kg body weight) for 4 weeks. At the end of the experiment, blood was drawn, and rats were then sacrificed, and their livers and pancreases were dissected for biochemical and histological assays. The level of fasting blood glucose and glycosylated hemoglobin significantly increased but amylase, insulin, and hepatic glycogen level decreased in the STZ group. PYC significantly augmented these effects in STZ + PYC group. The STZ group showed elevated level of nitric oxide, tumor necrosis factor-α, and interleukin-1beta in serum which were decreased by PYC treatment. Moreover, PYC significantly ameliorated increased thiobarbituric reactive substances, protein carbonyl, and decreased levels of glutathione, glutathione-s-transferase, and catalase activity in the liver and pancreas of the STZ rats. Histopathological and immunohistochemical examination also revealed a remarkable protective effect of PYC. The study suggests that PYC is effective in reducing diabetic-related complications in a type I model of diabetes and might be beneficial for the treatment of diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=84873088642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873088642&partnerID=8YFLogxK

U2 - 10.1007/s00709-012-0418-2

DO - 10.1007/s00709-012-0418-2

M3 - Article

C2 - 22660838

AN - SCOPUS:84873088642

VL - 250

SP - 347

EP - 360

JO - Protoplasma

JF - Protoplasma

SN - 0033-183X

IS - 1

ER -